Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to post earnings per share of ($1.17) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Ascendis Pharma A/S’s earnings. The highest EPS estimate is ($0.99) and the lowest is ($1.30). Ascendis Pharma A/S reported earnings per share of ($1.08) during the same quarter last year, which suggests a negative year-over-year growth rate of 8.3%. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 27th.
On average, analysts expect that Ascendis Pharma A/S will report full year earnings of ($3.86) per share for the current fiscal year, with EPS estimates ranging from ($4.13) to ($3.28). For the next financial year, analysts forecast that the company will report earnings of ($3.37) per share, with EPS estimates ranging from ($5.55) to ($0.44). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Ascendis Pharma A/S.
Several equities analysts have recently commented on ASND shares. Leerink Swann raised shares of Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $73.00 to $90.00 in a research note on Thursday, January 24th. Wedbush set a $81.00 price objective on shares of Ascendis Pharma A/S and gave the company a “buy” rating in a research note on Friday, January 25th. Zacks Investment Research downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Cantor Fitzgerald started coverage on shares of Ascendis Pharma A/S in a research note on Wednesday, January 23rd. They set an “overweight” rating and a $102.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their price objective on shares of Ascendis Pharma A/S from $85.00 to $145.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $123.67.
Shares of NASDAQ:ASND opened at $119.07 on Thursday. The stock has a market cap of $5.00 billion, a PE ratio of -27.50 and a beta of 0.91. Ascendis Pharma A/S has a 12 month low of $53.21 and a 12 month high of $131.76.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Further Reading: How Short Selling Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.